IQVIA Holdings Inc. $IQV Stock Holdings Decreased by American Century Companies Inc.

American Century Companies Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 24.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,244,425 shares of the medical research company’s stock after selling 399,027 shares during the period. American Century Companies Inc. owned about 0.73% of IQVIA worth $236,366,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Physician Wealth Advisors Inc. boosted its position in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of IQVIA during the third quarter worth approximately $36,000. Asset Dedication LLC increased its holdings in IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares in the last quarter. Finally, Rothschild Investment LLC raised its position in IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of research analyst reports. Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. JPMorgan Chase & Co. cut their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on IQVIA in a research report on Friday, February 6th. Finally, Evercore reaffirmed an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Trading Up 5.0%

Shares of IQV stock opened at $179.09 on Friday. The company has a market capitalization of $30.39 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.37. The firm has a 50 day moving average price of $212.19 and a two-hundred day moving average price of $208.00. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.